Popular Articles

Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. The international safety and efficacy trial, known as HORIZON, is designed to evaluate the potential benefits of dimebon on cognition (thinking and memory) in patients with Huntington disease. The companies also announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to dimebon for the treatment of Huntington disease. Buy arimidex to treat cancer.

14.3 Million Midwives, Nurses And Doctors Demand Action On Maternal Deaths At July G8 Summit
In an unprecedented move today, millions of midwives, nurses and doctors across the world delivered a message to G8 leaders to take urgent action to prevent women dying needlessly in pregnancy and childbirth.

generic viagra online


News of the day
New Data Show Cost Savings Achieved By Treating Mild And Moderate Alzheimer's Patients With Aricept(R)
Researchers attending the annual meeting of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR), heard today that prescribing Aricept® (donepezil hydrochloride) as soon as patients are diagnosed with either mild or moderate Alzheimer"s disease saves the NHS money. The findings contradict the recommendation by NICE that these medicines are not cost effective in the early stages of the disease, a decision that has been the subject of much recent debate.
Nutrition

Study Gives Clues To Increasing X-Rays' Power

Three-dimensional, real-time X-ray images of patients could be closer to reality because of research recently completed by scientists at the University of Nebraska-Lincoln and a pair of Russian institutes. In a paper to be published in an upcoming edition of Physical Review Letters, UNL Physics and Astronomy Professor Anthony Starace and his colleagues give scientists important clues into how to unleash coherent, high-powered X-rays. "This could be a contributor to a number of innovations," Starace said. Starace"s work focuses on a process called high-harmonic generation, or HHG. X-ray radiation can be created by focusing an optical laser into atoms of gaseous elements - usually low-electron types such as hydrogen, helium, or neon. HHG is the process that creates the energetic X-rays when the laser light interacts with those atoms" electrons, causing the electrons to vibrate rapidly and emit X-rays. But the problem with HHG has been around almost as long as the onset of the method in 1988: The X-ray light produced by the atoms is very weak. In an effort to make the X-rays more powerful, scientists have attempted using higher-powered lasers on the electrons, but success has been limited. "Using longer wavelength lasers is another way to increase the energy output of the atoms," Starace said. "The problem is, the intensity of the radiation (the atoms) produce drops very quickly." Instead of focusing on low-electron atoms like hydrogen and helium, Starace"s group applied HHG theory to heavier (and more rare) gaseous atoms having many electrons - elements such as xenon, argon and krypton. They discovered that the process would unleash high-energy X-rays with relatively high intensity by using longer wavelength lasers (with wavelengths within certain atom-specific ranges) that happen to drive collective electron oscillations of the many-electron atoms. "If you use these rare gases and shine a laser in on them, they"ll emit X-Rays with an intensity that is much, much stronger (than with the simple atoms)," Starace said. "The atomic structure matters." Starace said that unlocking the high-powered X-rays could lead one day, for example, to more powerful and precise X-ray machines. For instance, he said, heart doctors might conduct an exam by scanning a patient and creating a 3D hologram of his or her heart, beating in real time. Nanoscientists, who study the control of matter on an atomic or molecular scale, also may benefit from this finding, Starace said. Someday, the high-intensity X-rays may be used to make 3D images of the microscopic structures with which nanoscientists work. "With nanotechnology, miniaturization is the order of the day," he said. "But nanoscientists obviously could make use of a method to make the structures they"re building and working with more easily visible." The work is sponsored through funding by the National Science Foundation. Starace said NSF"s sponsorship made the collaboration with his Russian colleagues - Mikhail V. Frolov, N.L. Manakov and T.S. Sarantseva of Voronezh State University, and M.Y. Emelin and M.Y. Ryabikin of the Russian Academy of Sciences - possible. Frolov worked with Starace at UNL from 2002-2004 when he was a postdoctoral research associate in the Department of Physics and Astronomy. He has returned to Lincoln a number of times to collaborate with Starace on the HHG research. Frolov is a Ph.D. student of Manakov, with whom Starace has had a decade-long research collaboration that was initiated with support from NSF. Manakov also has an Adjunct Professor of Physics appointment in the UNL Department of Physics and Astronomy. Steve Smith University of Nebraska-Lincoln


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):